JP2011512123A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011512123A5 JP2011512123A5 JP2010543441A JP2010543441A JP2011512123A5 JP 2011512123 A5 JP2011512123 A5 JP 2011512123A5 JP 2010543441 A JP2010543441 A JP 2010543441A JP 2010543441 A JP2010543441 A JP 2010543441A JP 2011512123 A5 JP2011512123 A5 JP 2011512123A5
- Authority
- JP
- Japan
- Prior art keywords
- liver
- derived peptide
- seq
- pres
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims 22
- 150000001875 compounds Chemical class 0.000 claims 17
- 150000001413 amino acids Chemical class 0.000 claims 15
- 230000002209 hydrophobic effect Effects 0.000 claims 11
- 208000019423 liver disease Diseases 0.000 claims 11
- 210000004185 liver Anatomy 0.000 claims 10
- 241000700721 Hepatitis B virus Species 0.000 claims 9
- 239000008194 pharmaceutical composition Substances 0.000 claims 7
- 239000003814 drug Substances 0.000 claims 6
- 210000003494 hepatocyte Anatomy 0.000 claims 6
- 230000003612 virological effect Effects 0.000 claims 6
- 230000010933 acylation Effects 0.000 claims 5
- 238000005917 acylation reaction Methods 0.000 claims 5
- 229940079593 drug Drugs 0.000 claims 5
- 239000003112 inhibitor Substances 0.000 claims 5
- 230000002265 prevention Effects 0.000 claims 5
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims 4
- 108090000623 proteins and genes Proteins 0.000 claims 4
- 102000004169 proteins and genes Human genes 0.000 claims 4
- 239000013603 viral vector Substances 0.000 claims 4
- 208000005331 Hepatitis D Diseases 0.000 claims 3
- 239000002872 contrast media Substances 0.000 claims 3
- 238000003745 diagnosis Methods 0.000 claims 3
- 208000006454 hepatitis Diseases 0.000 claims 3
- 231100000283 hepatitis Toxicity 0.000 claims 3
- 208000002672 hepatitis B Diseases 0.000 claims 3
- 208000015181 infectious disease Diseases 0.000 claims 3
- 230000004048 modification Effects 0.000 claims 3
- 238000012986 modification Methods 0.000 claims 3
- 125000001419 myristoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 3
- 108010091867 peptide P Proteins 0.000 claims 3
- 229940002612 prodrug Drugs 0.000 claims 3
- 239000000651 prodrug Substances 0.000 claims 3
- 125000006850 spacer group Chemical group 0.000 claims 3
- 102000007698 Alcohol dehydrogenase Human genes 0.000 claims 2
- 108010021809 Alcohol dehydrogenase Proteins 0.000 claims 2
- 108091035707 Consensus sequence Proteins 0.000 claims 2
- 102000018832 Cytochromes Human genes 0.000 claims 2
- 108010052832 Cytochromes Proteins 0.000 claims 2
- 229940124226 Farnesyltransferase inhibitor Drugs 0.000 claims 2
- 206010019663 Hepatic failure Diseases 0.000 claims 2
- 102000014150 Interferons Human genes 0.000 claims 2
- 108010050904 Interferons Proteins 0.000 claims 2
- 102000035195 Peptidases Human genes 0.000 claims 2
- 108091005804 Peptidases Proteins 0.000 claims 2
- 241000700605 Viruses Species 0.000 claims 2
- ORILYTVJVMAKLC-UHFFFAOYSA-N adamantane Chemical compound C1C(C2)CC3CC1CC2C3 ORILYTVJVMAKLC-UHFFFAOYSA-N 0.000 claims 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 2
- 150000001408 amides Chemical class 0.000 claims 2
- 235000012000 cholesterol Nutrition 0.000 claims 2
- 238000002591 computed tomography Methods 0.000 claims 2
- 238000012217 deletion Methods 0.000 claims 2
- 230000037430 deletion Effects 0.000 claims 2
- 235000014113 dietary fatty acids Nutrition 0.000 claims 2
- 229930195729 fatty acid Natural products 0.000 claims 2
- 239000000194 fatty acid Substances 0.000 claims 2
- 150000004665 fatty acids Chemical class 0.000 claims 2
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims 2
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims 2
- 229940079322 interferon Drugs 0.000 claims 2
- 229940043355 kinase inhibitor Drugs 0.000 claims 2
- 231100000835 liver failure Toxicity 0.000 claims 2
- 208000007903 liver failure Diseases 0.000 claims 2
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 claims 2
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 claims 2
- 239000003757 phosphotransferase inhibitor Substances 0.000 claims 2
- -1 polycyclic aromatic compounds Chemical class 0.000 claims 2
- 239000003528 protein farnesyltransferase inhibitor Substances 0.000 claims 2
- 125000003696 stearoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 2
- 238000006467 substitution reaction Methods 0.000 claims 2
- 244000052613 viral pathogen Species 0.000 claims 2
- HIXDQWDOVZUNNA-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-hydroxy-7-methoxychromen-4-one Chemical compound C=1C(OC)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=C(OC)C(OC)=C1 HIXDQWDOVZUNNA-UHFFFAOYSA-N 0.000 claims 1
- 102100027211 Albumin Human genes 0.000 claims 1
- 108010088751 Albumins Chemical class 0.000 claims 1
- 125000001433 C-terminal amino-acid group Chemical group 0.000 claims 1
- 150000008574 D-amino acids Chemical class 0.000 claims 1
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 claims 1
- 206010016654 Fibrosis Diseases 0.000 claims 1
- 229910052688 Gadolinium Inorganic materials 0.000 claims 1
- 229930186217 Glycolipid Natural products 0.000 claims 1
- 208000018565 Hemochromatosis Diseases 0.000 claims 1
- 206010019695 Hepatic neoplasm Diseases 0.000 claims 1
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims 1
- RRHGJUQNOFWUDK-UHFFFAOYSA-N Isoprene Chemical class CC(=C)C=C RRHGJUQNOFWUDK-UHFFFAOYSA-N 0.000 claims 1
- 241000282675 Lagothrix Species 0.000 claims 1
- 208000004554 Leishmaniasis Diseases 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- 208000001145 Metabolic Syndrome Diseases 0.000 claims 1
- 241001465754 Metazoa Species 0.000 claims 1
- 108090001074 Nucleocapsid Proteins Proteins 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- 229940079156 Proteasome inhibitor Drugs 0.000 claims 1
- 108020004459 Small interfering RNA Proteins 0.000 claims 1
- 229940122423 Viral RNA polymerase inhibitor Drugs 0.000 claims 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims 1
- 230000004913 activation Effects 0.000 claims 1
- 239000012190 activator Substances 0.000 claims 1
- 125000001931 aliphatic group Chemical group 0.000 claims 1
- 125000000539 amino acid group Chemical group 0.000 claims 1
- 230000030741 antigen processing and presentation Effects 0.000 claims 1
- 230000003115 biocidal effect Effects 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 230000037396 body weight Effects 0.000 claims 1
- 210000004899 c-terminal region Anatomy 0.000 claims 1
- 150000001735 carboxylic acids Chemical class 0.000 claims 1
- 230000015556 catabolic process Effects 0.000 claims 1
- 229940106189 ceramide Drugs 0.000 claims 1
- 150000001783 ceramides Chemical class 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 150000001841 cholesterols Chemical class 0.000 claims 1
- 230000007882 cirrhosis Effects 0.000 claims 1
- 208000019425 cirrhosis of liver Diseases 0.000 claims 1
- 230000009918 complex formation Effects 0.000 claims 1
- 230000002950 deficient Effects 0.000 claims 1
- 238000006731 degradation reaction Methods 0.000 claims 1
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 150000002148 esters Chemical class 0.000 claims 1
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims 1
- 230000006126 farnesylation Effects 0.000 claims 1
- 239000007850 fluorescent dye Substances 0.000 claims 1
- 239000012634 fragment Substances 0.000 claims 1
- UIWYJDYFSGRHKR-UHFFFAOYSA-N gadolinium atom Chemical compound [Gd] UIWYJDYFSGRHKR-UHFFFAOYSA-N 0.000 claims 1
- 238000001415 gene therapy Methods 0.000 claims 1
- 150000002314 glycerols Chemical class 0.000 claims 1
- 230000028993 immune response Effects 0.000 claims 1
- 230000002163 immunogen Effects 0.000 claims 1
- 238000007918 intramuscular administration Methods 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 claims 1
- 239000002502 liposome Substances 0.000 claims 1
- 210000005229 liver cell Anatomy 0.000 claims 1
- 230000003908 liver function Effects 0.000 claims 1
- 208000014018 liver neoplasm Diseases 0.000 claims 1
- 201000004792 malaria Diseases 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- 208000030159 metabolic disease Diseases 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 229920005615 natural polymer Chemical class 0.000 claims 1
- 108020004707 nucleic acids Proteins 0.000 claims 1
- 102000039446 nucleic acids Human genes 0.000 claims 1
- 150000007523 nucleic acids Chemical class 0.000 claims 1
- 229940127073 nucleoside analogue Drugs 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 125000001312 palmitoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 239000002245 particle Substances 0.000 claims 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 claims 1
- 239000000816 peptidomimetic Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 150000003904 phospholipids Chemical class 0.000 claims 1
- 229920001223 polyethylene glycol Chemical class 0.000 claims 1
- 239000002243 precursor Substances 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 claims 1
- 239000003207 proteasome inhibitor Substances 0.000 claims 1
- 230000002285 radioactive effect Effects 0.000 claims 1
- 102000009929 raf Kinases Human genes 0.000 claims 1
- 108010077182 raf Kinases Proteins 0.000 claims 1
- 230000010076 replication Effects 0.000 claims 1
- 239000003419 rna directed dna polymerase inhibitor Substances 0.000 claims 1
- 201000004409 schistosomiasis Diseases 0.000 claims 1
- 241000894007 species Species 0.000 claims 1
- 150000003431 steroids Chemical class 0.000 claims 1
- 238000007920 subcutaneous administration Methods 0.000 claims 1
- 239000000829 suppository Substances 0.000 claims 1
- 229920001059 synthetic polymer Chemical class 0.000 claims 1
- 150000007970 thio esters Chemical class 0.000 claims 1
- 150000003573 thiols Chemical class 0.000 claims 1
- 208000037972 tropical disease Diseases 0.000 claims 1
- 229960005486 vaccine Drugs 0.000 claims 1
- 239000003981 vehicle Substances 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US6234708P | 2008-01-25 | 2008-01-25 | |
| US61/062,347 | 2008-01-25 | ||
| PCT/EP2009/000477 WO2009092612A1 (en) | 2008-01-25 | 2009-01-26 | Hydrophobic modified pres-derived peptides of hepatitis b virus (hbv) and their use as vehicles for the specific delivery of compounds to the liver |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2011512123A JP2011512123A (ja) | 2011-04-21 |
| JP2011512123A5 true JP2011512123A5 (enExample) | 2012-03-08 |
| JP5686468B2 JP5686468B2 (ja) | 2015-03-18 |
Family
ID=40521848
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010543441A Expired - Fee Related JP5686468B2 (ja) | 2008-01-25 | 2009-01-26 | Ｂ型肝炎ウイルス（ＨＢＶ）の疎水性修飾されたｐｒｅＳ由来ペプチド及び肝臓に化合物を特異的に送達するためのビヒクルとしてのそれらの使用 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US9868768B2 (enExample) |
| EP (1) | EP2245047B1 (enExample) |
| JP (1) | JP5686468B2 (enExample) |
| CN (1) | CN102015753A (enExample) |
| ES (1) | ES2847288T3 (enExample) |
| WO (1) | WO2009092612A1 (enExample) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1281761A1 (en) | 2001-07-27 | 2003-02-05 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Hepatitis B virus pre-S1 derived synthetic polypeptides and their use thereof. |
| EP2117576B1 (en) | 2007-02-08 | 2014-04-16 | University Of Utah Research Foundation | Methods and compositions related to inhibition of viral entry |
| US8875361B2 (en) | 2008-05-21 | 2014-11-04 | Wirtz Manufacturing Co., Inc. | Reformed battery grids |
| SG178254A1 (en) * | 2009-08-07 | 2012-03-29 | Transgene Sa | Composition for treating hbv infection |
| CN102241744B (zh) * | 2010-05-14 | 2015-03-04 | 上海贺普药业股份有限公司 | 一种病毒感染阻断剂、其药物组合物及其应用 |
| WO2012106403A2 (en) * | 2011-02-01 | 2012-08-09 | Uab Research Foundation | Methods and compositions for pseudoinfectious alphaviruses |
| CN103402545B (zh) * | 2011-02-10 | 2017-04-05 | 海德堡鲁普雷希特卡尔斯大学 | 疏水性经修饰肽及其在肝特异性靶向中的用途 |
| US10363323B2 (en) | 2011-02-10 | 2019-07-30 | Ruprecht-Karls-Universitat Heidelberg | Hydrophobic modified peptides for liver specific diagnosis |
| EP2691105B1 (en) | 2011-03-28 | 2018-07-11 | University of Utah Research Foundation | Methods and compositions related to inhibition of viral entry |
| CN109354623B (zh) * | 2012-04-25 | 2022-06-24 | 华辉安健（北京）生物科技有限公司 | 乙肝肝炎病毒功能性受体的组成以及相关应用 |
| EP2703001A1 (en) | 2012-08-26 | 2014-03-05 | XAX Kft. | Tumor vaccination |
| CN103665095A (zh) * | 2012-09-11 | 2014-03-26 | 中国人民解放军军事医学科学院卫生学环境医学研究所 | 一种疏水性多肽修饰抗体的合成方法 |
| US8961995B2 (en) * | 2012-09-20 | 2015-02-24 | Uab Research Foundation | Methods and compositions for alphavirus replicons |
| EP2917231B1 (en) | 2012-11-12 | 2019-03-06 | Ruprecht-Karls-Universität Heidelberg | Lipopeptides for use in treating liver diseases and cardiovascular diseases |
| ES2922883T3 (es) * | 2014-10-07 | 2022-09-21 | Myr Gmbh | Tratamiento combinado de la infección por VHB y VHD |
| EP3138579A1 (en) * | 2015-09-05 | 2017-03-08 | Biomay Ag | Fusion protein for use in the treatment of a hepatitis b virus infection |
| EP3189850A1 (en) * | 2015-12-16 | 2017-07-12 | Ruprecht-Karls-Universität Heidelberg | Liver targeting of cyclic pres-derived peptides of hbv |
| EP3181146A1 (en) | 2015-12-16 | 2017-06-21 | Ruprecht-Karls-Universität Heidelberg | Cyclic ntcp-targeting peptides and their uses as entry inhibitors |
| CN109069577B (zh) | 2016-01-07 | 2022-08-19 | 纳维根公司 | Hiv进入的d-肽抑制剂以及使用方法 |
| WO2018054891A1 (en) | 2016-09-20 | 2018-03-29 | Ruprecht-Karls-Universität | Compounds and combinations thereof for preventing and/or treating hbv and/or hdv infections |
| EP3392267A1 (en) * | 2017-04-18 | 2018-10-24 | Myr GmbH | Therapy of atherosclerosis, primary biliary cirrhosis and nrlp3 inflammasome-associated disease by htcp inhibitors |
| CN109718364A (zh) * | 2017-10-27 | 2019-05-07 | 上海贺普药业股份有限公司 | 充分剂量条件下治疗乙肝病毒相关肝病的药物和方法 |
| US11497808B2 (en) | 2019-09-30 | 2022-11-15 | Gilead Sciences, Inc. | HBV vaccines and methods treating HBV |
| EP3804750A1 (en) | 2019-10-10 | 2021-04-14 | Universität Heidelberg | Conjugate compounds for preventing and/or treating hbv and/or hdv infections, liver diseases and for targeting ntcp |
| WO2021168575A1 (en) * | 2020-02-27 | 2021-09-02 | Quadrumix Biotechnology Inc. | Polypeptides directed against viral infection and uses thereof |
| JP2024535127A (ja) | 2021-09-14 | 2024-09-26 | アドファファーム ゲーエムベーハー | 新規リポペプチド製剤 |
| WO2025031397A1 (zh) * | 2023-08-08 | 2025-02-13 | 前沿生物药业(南京)股份有限公司 | 钠离子-牛磺胆酸共转运蛋白长效抑制剂及其应用 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5204096A (en) * | 1984-03-07 | 1993-04-20 | New York Blood Center, Inc. | Pre-S gene coded peptide hepatitis B immunogens, vaccines, diagnostics, and synthetic lipid vesicle carriers |
| EP1281761A1 (en) * | 2001-07-27 | 2003-02-05 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Hepatitis B virus pre-S1 derived synthetic polypeptides and their use thereof. |
| CN101045156B (zh) | 2006-03-29 | 2012-05-02 | 刘宏利 | 特异靶向性药物及其用途 |
| WO2008103380A2 (en) * | 2007-02-21 | 2008-08-28 | Fox Chase Cancer Center | Hepatitis b virus compositions and methods of use |
-
2009
- 2009-01-26 JP JP2010543441A patent/JP5686468B2/ja not_active Expired - Fee Related
- 2009-01-26 ES ES09704030T patent/ES2847288T3/es active Active
- 2009-01-26 WO PCT/EP2009/000477 patent/WO2009092612A1/en not_active Ceased
- 2009-01-26 EP EP09704030.7A patent/EP2245047B1/en not_active Not-in-force
- 2009-01-26 US US12/864,197 patent/US9868768B2/en active Active
- 2009-01-26 CN CN2009801125069A patent/CN102015753A/zh active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011512123A5 (enExample) | ||
| JP5791900B2 (ja) | Ｂ型肝炎ウイルス（ＨＢＶ）の疎水性改変ｐｒｅＳ由来ペプチドならびにＨＢＶ侵入インヒビターおよびＨＤＶ侵入インヒビターとしてのそれらの使用 | |
| JP7362142B2 (ja) | 環状ｎｔｃｐ標的化ペプチドおよび侵入阻害剤としてのその使用 | |
| US9868768B2 (en) | Hydrophobic modified pres-derived peptides of hepatitis B virus (HBV) and their use as vehicles for the specific delivery of compounds to the liver | |
| EP3204030B1 (en) | Combination therapy of hbv and hdv infection | |
| JP7672677B2 (ja) | 全用量条件下でｂ型肝炎ウイルス関連肝疾患を治療する医薬品および方法 | |
| WO2024193905A1 (en) | Hbv antigen formulation for treating hepatitis b | |
| EP3189850A1 (en) | Liver targeting of cyclic pres-derived peptides of hbv | |
| HK40083480A (en) | Combination therapy of hbv and hdv infection | |
| HK1150168B (en) | Hydrophobic modified pres-derived peptides of hepatitis b virus (hbv) and their use as hbv and hdv entry inhibitors | |
| EA047071B1 (ru) | Комбинированная терапия вызываемой вирусами hbv и hdv инфекции |